Fulcrum Therapeutics (NASDAQ:FULC) Earns “Sector Perform” Rating from Royal Bank of Canada

Fulcrum Therapeutics (NASDAQ:FULC)‘s stock had its “sector perform” rating reiterated by equities research analysts at Royal Bank of Canada in a report released on Thursday,Benzinga reports. They currently have a $4.00 price objective on the stock. Royal Bank of Canada’s target price indicates a potential upside of 19.05% from the company’s previous close.

Several other analysts have also recently commented on the company. Leerink Partners reissued a “market perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. HC Wainwright reissued a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Finally, Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $22.00 to $3.00 in a report on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Down 5.6 %

NASDAQ FULC traded down $0.20 during trading hours on Thursday, hitting $3.36. 170,751 shares of the stock were exchanged, compared to its average volume of 986,755. The company has a market cap of $209.67 million, a price-to-earnings ratio of -10.84 and a beta of 2.24. Fulcrum Therapeutics has a 12-month low of $2.87 and a 12-month high of $13.70. The stock has a 50-day moving average of $3.97 and a 200 day moving average of $6.53.

Institutional Trading of Fulcrum Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of FULC. National Bank of Canada FI grew its holdings in Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Fulcrum Therapeutics in the third quarter valued at approximately $59,000. Intech Investment Management LLC acquired a new position in shares of Fulcrum Therapeutics in the third quarter valued at approximately $62,000. Finally, Profund Advisors LLC purchased a new position in shares of Fulcrum Therapeutics during the second quarter valued at approximately $68,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.